Study Suggests CRISPR Could Be Used to Create Hypoallergenic Cats

Recent research published in PNAS Nexus suggests that gene editing could pave the way for hypoallergenic cats by targeting the genes responsible for producing Fel d 1, a major cat allergen. Approximately 15% of people are allergic to cats, with symptoms ranging from mild to severe. The allergen, Fel d 1, is produced in various glands of cats, and its exact function remains unknown. However, it is believed to play roles in immune regulation, skin protection, or chemical communication among cats.

Researchers led by Martin D. Chapman from InBio focused on the CH1 and CH2 genes that encode Fel d 1. Through sequence analysis of these genes across 276 domestic and exotic cats, including cougars and cheetahs, they discovered significant variability. This variability suggests that Fel d 1 might not be essential for cats. In fact, some wildcats, like the black-footed cat and cougar, possess mutations that likely inhibit Fel d 1 expression without apparent health issues.

The study indicates that CH1 and CH2 have been under selective pressure, potentially providing some evolutionary advantage. However, low conservation levels between species imply that Fel d 1's function may differ among cat species or be nonessential. This is supported by evidence of healthy cats lacking the CH2 gene due to CRISPR modifications.

CRISPR technology offers a promising approach to delete the CH1 and CH2 genes in domestic cats, potentially leading to hypoallergenic breeds. This gene-editing technique could reduce the production of Fel d 1, thereby alleviating allergic reactions in humans. While further research is needed to fully understand Fel d 1's role and ensure the safety of gene-edited cats, this study marks a significant step toward addressing cat allergies through genetic modification.